Roberto Mignone Sells 286,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $22.77 on Friday. The firm has a market capitalization of $25.80 billion, a P/E ratio of -26.79, a PEG ratio of 0.99 and a beta of 0.79. The stock has a fifty day moving average price of $18.25 and a 200 day moving average price of $17.71. Teva Pharmaceutical Industries Limited has a 52 week low of $10.39 and a 52 week high of $22.80. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of research analyst reports. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. UBS Group upped their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Barclays upped their price objective on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.88.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently added to or reduced their stakes in the business. UMB Bank n.a. increased its stake in Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after acquiring an additional 2,067 shares during the last quarter. Smithfield Trust Co increased its stake in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth about $50,000. Claro Advisors LLC acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth about $52,000. Finally, Venturi Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth about $60,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.